EAM Investors’s Galectin Therapeutics GALT Stock Holding History

EAM Investors’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-218,429	Closed	-$1.39M	–	331
2018 Q2	$1.39M	Sell	218,429 -100,758	-32%	-$491K	0.22%	175
2018 Q1	$1.51M	Buy	+319,187	New	+$1.49M	0.25%	160
2014 Q2	–	Sell	-161,935	Closed	-$2.48M	–	335
2014 Q1	$2.48M	Buy	+161,935	New	+$2.31M	0.45%	53
2013 Q4	–	Sell	-152,854	Closed	-$1.52M	–	328
2013 Q3	$1.52M	Buy	+152,854	New	+$1.03M	0.3%	119

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

FFA

First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return

BCA

Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

EAM Investors's GALT Position: Q3 2018 in Review

EAM Investors sold out of Galectin Therapeutics (GALT) in Q3 2018, closing a stake of 218,429 shares — an estimated $1.39M sold.

EAM Investors first reported a position in GALT in Q3 2013 and held it in 4 quarters. The position peaked at $2.48M in Q1 2014. 60 funds tracked by Wall St. Rank hold GALT as of Q3 2018.

EAM Investors reported no remaining Galectin Therapeutics position as of Q3 2018 after selling out during the quarter.
EAM Investors sold 218,429 Galectin Therapeutics shares in Q3 2018, an estimated $1.39M.
EAM Investors first reported a position in Galectin Therapeutics in Q3 2013 and held it in 4 quarters.
EAM Investors's Galectin Therapeutics position peaked at $2.48M in Q1 2014.
60 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2018.

Based on EAM Investors's 13F filing for Q3 2018, filed 8 Nov 2018.